We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

MINDRAY In-Vitro Diagnostics

As a global leader in in-vitro diagnostics, Mindray provides a wide range of efficient, reliable IVD solutions for la... read more Featured Products: More products

Download Mobile App




Mindray Launches BC-700 Series Integrated CBC and ESR Hematology Analyzer for Small-to-Mid Sized Labs

By LabMedica International staff writers
Posted on 17 Mar 2022
Print article
Image: BC-700 Series Integrated CBC and ESR Hematology Analyzer (Photo courtesy of Mindray)
Image: BC-700 Series Integrated CBC and ESR Hematology Analyzer (Photo courtesy of Mindray)

Traditionally, erythrocyte sedimentation rate (ESR) tests, which measure how quickly red blood cells (RBCs) settle in diluted plasma over a specified period of time, are performed on an independent analyzer, and can take up to 60 minutes to get the results. However, there is a need for integrated testing for CBC and ESR. Now, the first all-in-one hematology solution that combines 5-part differential with ESR analysis yields both CBC and ESR results with just one test in merely 1.5 minutes, significantly improving workflow and testing efficiency while benefiting patients with quicker blood test reports.

Mindray (Shenzhen, China) has launched the new BC-700 Series, a revolutionary hematology analyzer series that incorporates both complete blood count (CBC) and erythrocyte sedimentation rate (ESR) tests. The BC-700 Series, including two open vial models BC-700/BC-720 and two autoloader models BC-760/BC-780, is designed to empower medium-volume laboratories with advanced diagnostics technologies that are applied in the premium products.

Striving to benefit more laboratories worldwide, the BC-700 Series adopts Mindray’s core hematology technology of SF Cube 3D analysis and is built from the same platform as its high-end BC-6000 Series, but in a smaller footprint. In SF Cube technology, target cells are subject to a 3D analysis using bi-angular laser scatter signals and fluorescence. The 3D scattergrams generated with the cellular information can help clinical experts to identify and differentiate cell populations, in particular abnormal clusters, providing a more reliable result to the doctor.

Powered by the SF Cube analysis technology, Mindray has developed many useful hematology parameters. With the new parameter, PLT-H, the BC-700 Series can more easily address the challenges that were previously inadequately met by conventional hematology analyzers, providing an accurate optical platelet count result in every CBC and DIFF test. By using patented reagents with cutting-edge technology, the BC-700 Series also allows the platelet clumps to be de-aggregated, offering laboratories a complete solution for reliable platelet analysis.

"We designed and built this analyzer series, because Mindray believes all labs matter. Every laboratory needs solutions that empower trust and accurate results, and this is what drives us to develop technologies and innovations that go above and beyond your requirements," said Shane Wan, Director of International IVD Product Line, Mindray.

Related Links:
Mindray 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.